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1208-65 Favorable Clinical Outcome in Patients With 
Cardiogenic Shock Due to Fulminant Myocarditis 
Supported by Extracorporeal Membrane Oxygenation: 
Comparison With Those With Acute (Nonfulminant) 
Myocarditis 
Yasuhide Asaumi, Satoshi Yasuda, lsao Morii, Hiroyuki Kakuchi, Yoritaka Otsuka, 
Atsushi Kawamura, Hiroshi Nonogi, Yoshikado Sasako, Shunichi Miyazaki, National 
Cardiovascular Center, Suita, Japan 
Background: The application of extracorporeal membrane oxygenation (ECMO) wtth 
percutaneous cardiopulmonary bypass has been recently extended to temporaiy circula- 
tory support in patients with fulminant myocarditis. However, the survival and prognosis 
of patients who are particularly ill remain poorly understood. Methods: Patients with 
myocarditis were divided into the following two groups. Fourteen patients who required 
ECMO for cardiogenic shock were defined as having fulminant myocarditis (F group), 
whereas 13 patients who had acute onset of symptoms but did not have compromised 
hemodynamics were defined as having acute (nonfulminant) myocarditis (non-F group). 
Results: In F group, 10 patients were successfully weaned from ECMO. Therefore, the 
overall survival rate at the time of discharge was 71%. Between patients who died (D) 
and those survived (S) in F group. there were significant differences (PcO.05) in left ven- 
tricular end-diastolic dimension (D:36& vs S:50*2 [mean&EM] mm), end-systolic 
dimension (D:34+6 vs S:45+2mm), wall thickness (D:15+1 vs S:l lilmm). maxCPK-MB 
levels (D:353*145 vs S:120+35U/L) and serum creatinine levels (D:2.1*0.5 vs 
S:l.O+O.lmg/dl). Compared with the non-F group, the fractional shortening in the F group 
was more severely depressed in the acute phase (F:lOil vs non-F:23*3%, P<O.O5), but 
recovered in the chronic phase (F:30*2 vs non-F:33*3%, P=NS). Rates for adverse clin- 
ical events were also similar between the F and non-F groups during the follow-up period 
of 36 months on average. Conclusions: In patients with fulminant myocarditis, a hemo- 
dynamic support using ECMO results in excellent swival. Once a patient recovers from 
inflammatory myocardial damage, the subsequent clinical outcome is favorable, similar 
to that observed in patients with acute (nonfulminant) myocardltis. 
1208-66 In Vitro Evaluation of the Concept of Pericardial 
Pressure Augmentation in Isolated Pig Hearts 
Markus Ferrari, Markus Schlosser, Gerald S. Werner, Hans R. Figulla, Friedrich-Schiller- 
University, Jena. Germany 
Introduction: Acute right heart failure is an unsolved problem in cardiology and cardio- 
vascular surgery. Mechanical circulatory support devices primarily focus on left ventricu- 
lar failure. Assist devices supporting the right ventricle require major surgery for implant, 
and for its explant. Thus, we thought for a method of minimal invasive right ventricular 
support by pericardialpressure augmentation (PPA). 
Methods: For evaluation of the concept of PPA we built a tulip shaped prototype of the 
dewce covering the apical two thirds of the heart. It consists of two elastic foils with a 
helium gas filled space in between which is inflated and deflated by the driving console of 
an intra-aortic balloon pump. The outer non-compliant foil stabilizes the sac. The inner 
sac transfers the pressure augmentation directly to the epicardium therefore to the heaft. 
Due to differences in myocardlal thickness this technique of pericardial compression 
mainly supports the right ventricle. For in-vitro evaluation of this novel technique of PPA 
we tested the concept of PPA in 8 isolated pig hearts. 
Results: Under PPA with 60 I minute we recorded average right ventricular pressures of 
31.3 +I- 4.42 mmHg during systole, and 1.4 +//- 1.60 mmHg during diastole. Left ventricu- 
lar pressures were 23.7 +/- 5.06 mmHg, and 0.7 +/- 1.25 mmHg respectively. An outflow 
of 200 ml I minute through the pulmonary artery was obtained in the artificial circulation. 
Conclusion: This in-vitro evaluation demonstrates the feasibility of pericardial pressure 
augmentation for right ventricular support. The concept of PPA offers an option of mini- 
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Conclusion: Compared to IABP the new catheter based intracardiac pump significantly 
improves cardiac and systemic hemodynamics during acute mitral regurgitation. This 
minipump may fill the gap in the range of cardiac assist devices between standard IAEP 
and current LV assist device alternatives. 
1208-68 Left Ventricular Diastolic Filling Pattern by Passive 
Ventricular Reshaping in Canine Heart Failure 
Abul Kashem Deborah L. Crabbe, Sarmina Hassan, David B. Melvin, Bruce I. Goldman, -1 
William P. Santamore, Temple University, Philadelphia, PA, University of Cincinnati, 
Cincinnati, OH 
Background: End-stage heart failure is associated with significant alterations in left ven- 
tricular (LV) geometry leading to increases in wall stress and reduced LV contractility. 
CardioClaspTM is a passive restraint device designed to normalize LV geometry and 
reduce wall stress. Improvement in wall stress should be associated with improved dias- 
tolic filling parameters. 
Methods: In dogs (n=lO; 22-26 kg) rapid ventricular pacing (210 ppm, week one. to 240 
ppm week 4) induced decompensated heart failure. Hemodynamic data were obtained 
before and after CardioClaspTM placement. FractIonal area of contraction was measured 
by direct epicardial echocardiography at baseline and with CardioClaspTM. Using transe- 
sophageal echocardiography, pulse wave Doppler measurements of standard mitral 
inflow were obtained in a sub-set of animals (n=5). Data represented here are expressed 
as mean&EM. Results: In-viva overall, CardioClasp TM, decreased end-diastolic LV 
anterior-posterior dimension by 21.2 + 3.9%. LV wall stress was sigmficantly reduced by 
26.6 f 2.1% with CardioClasp? In association with these changes in geometry, frac- 
tional area change increased from 21.6 * 3.6 to 29.7 f 6.0 (p=O.O4). In the subset group, 
peak e wave velocity (56.6 * 6.2 vs. 63.9 f 7.6 cm/set; p=O.20) and e/a ratio (2.0 f 0.2 
vs. 2.1 + 0.3; p=O.ll) remained unchanged with CardioClaspTM placement, however, 
deceleration time was increased from 69.4 + 12.1 to 107.0 * 14.3 msec: (p=O.O3), sug- 
gesting changes in LV compliance with the device. Conclusions: CardioclaspTM was 
able to reshape the ventricle and reduce the wall stress. CardioClaspTM is associated 
with a more favorable geometry, improved systolic performance and LV compliance. 
1208-69 First Clinical Experience With the lmpellafi Micropump 
in Patients With Cardiogenic Shock 
mal invasive implantation, and non-surgical removing of a pericardial device. However, Joseoh Dens W. Flameng, P. Sergeant, P. Herijgers, B. Meyns, University Hospitals 
animal experiments and techntcal improvements of the device are required for further Leuven, Leuven, Belgium 
evaluation of this novel technique in the future 
Objectives To assess safetv, feasibilitv and efficacv of the ImoellaB ourno in oatients 
1208-67 New lmpella Intracardiac Minipump Supports the 
Acutely Failing Left Heart Significantly More Effective 
Than lntraortic Balloon Pumping 
.., 
with cardiogenic shock.Background Animal experiments showed left ventricular unload- 
ing and improved haemodynamics with the Impella micro-axial blood pump. Methods 
From January 2001 through April 2002, 12 patients in cardiogenic shock (on maximal 
inotropic support and with IABP in 6 cases) underwent left ventricle unloading with the 
Koen Reesink Andre Dekker, Theo van der Nagel, Erik van der Veen. Vincent van 
Ommen, Yuri Ganushak. Gijs Geskes, Ceclle Soemers, Jos Maessen, Cardiovascular 
Research Institute Maastricht, Maastricht, The Netherlands 
Background: The Impella intracardiac minipump (IMP) is a new, percutaneous LV 
unloading device recently introduced clinically. The IMP features a 6 mm diameter inte- 
grated cannula-pump assembly with a capacity of 4.5 Ilmin for use in trans aortic valve 
position. The efficacy of the IMP has yet to be established. We tested the hypothesis that 
this device can provide more effective left heari support than IABP in acute heart failure. 
Methods: Reversible acute mitral regurgitation (AMR) was induced in calves (n=6) by 
stenting the mitral valve using a vena cava filter. In each animal full IMP assist was com- 
Impella@ micro-axial pump. Four were placed via the femoral artery (PC1 patients) and 6 
directly through the aorta (postcardiotomy heart failure). Mean age was 60 years (range 
43-75), 6 were’ male. Mean CPl$,, level was 5442 U/L (195.17936). Results A stable 
pump flow of 3.6 +I .l Umln. was reached. Mean blood pressure before Impella@support 
was 61.5 *12.7 mmHg and increased to 75 e26.3 after 6 hours and 75.7 ~16.6 mmHg 
(p=O.O36) after 24 hours. Cardiac output increased from 3.6 t1.2 Llmin to 5.7 e1.5 
(p=O.O04) and 5.9 22.0 Lfmln (p=O.Ol) at 6 and 24 hours. Mean pulmonary wedge pres- 
sure decreased from 20.7 e13.2 mmHg to 13.6 +7.3 and 16 k7.4 mmHg at 6 and 24 
hours (NS). Blood lactate levels decreased significantly after 6 hours of support (from 4.1 
k2.9 to 2.1 +1.7 mmollL, p=O.OOS). Free plasma haemoglobin levels were initially high 
(107.7 * 61.7mgldl at 6 hours) and decreased to 50 mgldl afterwards. Eight patients 
